Kanika Kalra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kanika Kalra has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anton Camaj
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30308, USA
1 shared publication Daisuke Onohara
Structural Heart Research & Innovation Laboratory, Carlyle Fraser Heart Center, Emory University Hospital Midtown, Atlanta, GA; Nationwide Children's Hospital, Columbus, Ohio
1 shared publicationDongyang Xu
Structural Heart Research & Innovation Laboratory, Carlyle Fraser Heart Center, Emory University Hospital Midtown, Atlanta, GA; Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA
1 shared publication- Joe X. Xie
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30308, USA
1 shared publication - Kendra J. Grubb
Emory University School of Medicine, Atlanta, Georgia, USA
1 shared publication Kirthana Sreerangathama Suresh
Structural Heart Research & Innovation Laboratory, Carlyle Fraser Heart Center, Emory University Hospital Midtown, Atlanta, GA; Nyra Medical Inc, Atlanta, GA
1 shared publication
Latest Publications
- 15 May 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (1) , 142-152.e1
Surgical repair of functional tricuspid regurgitation by drawing the anterior and posterior papillary muscles towards the septum, corrected regurgitation and restored physiologic valve kinematics
- 15 May 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (1) , 142-152.e1
Surgical repair of functional tricuspid regurgitation by drawing the anterior and posterior papillary muscles towards the septum, corrected regurgitation and restored physiologic valve kinematics
- Open Access
- 31 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6565
Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Bicuspid Aortic Valve Stenosis—We Need a Well-Designed Randomized Control Trial
Bicuspid aortic stenosis is a common pathology, typically seen in patients a decade younger than those with tricuspid valves. Surgical aortic valve replacement has been the mainstay treatment for bicuspid disease, especially considering the prevalence of concomitant aortic aneurysmal pathology. Transcatheter aortic valve replacement has shown equivalent results in bicuspid compared to tricuspid pathology in highly selected patient populations in single-arm registries and observational studies. For older patients with favorable bicuspid pathology, TAVR is reasonable. However, as younger patients with longer life expectancy are now being treated with TAVR, what is “best” is a question only answered by a well-designed randomized controlled trial. Herein, we describe the current evidence for treating bicuspid aortic stenosis and provide a framework for future trials. Yet, the question of equipoise remains, and who will we enroll?
- 31 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6565
Open AccessTranscatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Bicuspid Aortic Valve Stenosis—We Need a Well-Designed Randomized Control Trial
Bicuspid aortic stenosis is a common pathology, typically seen in patients a decade younger than those with tricuspid valves. Surgical aortic valve replacement has been the mainstay treatment for bicuspid disease, especially considering the prevalence of concomitant aortic aneurysmal pathology. Transcatheter aortic valve replacement has shown equivalent results in bicuspid compared to tricuspid pathology in highly selected patient populations in single-arm registries and observational studies. For older patients with favorable bicuspid pathology, TAVR is reasonable. However, as younger patients with longer life expectancy are now being treated with TAVR, what is “best” is a question only answered by a well-designed randomized controlled trial. Herein, we describe the current evidence for treating bicuspid aortic stenosis and provide a framework for future trials. Yet, the question of equipoise remains, and who will we enroll?